HighVista Strategies LLC Buys 59,193 Shares of Liquidia Co. (NASDAQ:LQDA)

HighVista Strategies LLC raised its holdings in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 48.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 180,947 shares of the company's stock after acquiring an additional 59,193 shares during the quarter. HighVista Strategies LLC owned approximately 0.24% of Liquidia worth $1,809,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LQDA. Quest Partners LLC acquired a new stake in Liquidia in the 2nd quarter valued at about $27,000. Hilltop National Bank acquired a new stake in Liquidia during the second quarter worth about $33,000. Deuterium Capital Management LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at approximately $120,000. Clear Harbor Asset Management LLC bought a new position in Liquidia in the third quarter valued at approximately $100,000. Finally, Signaturefd LLC increased its stake in shares of Liquidia by 38,400.0% in the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company's stock valued at $100,000 after purchasing an additional 9,984 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Stock Up 0.3 %

Shares of LQDA stock traded up $0.03 during trading hours on Tuesday, reaching $11.26. The company had a trading volume of 1,423,986 shares, compared to its average volume of 763,961. The business has a fifty day simple moving average of $10.76 and a 200-day simple moving average of $11.34. Liquidia Co. has a 12 month low of $6.83 and a 12 month high of $16.99.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Bank of America dropped their target price on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating for the company in a report on Tuesday, August 20th. Raymond James upgraded Liquidia from an "outperform" rating to a "strong-buy" rating in a report on Monday, August 19th. Scotiabank initiated coverage on shares of Liquidia in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $19.00 price target on shares of Liquidia in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Liquidia has an average rating of "Moderate Buy" and a consensus target price of $24.00.

Insiders Place Their Bets

In related news, CEO Roger Jeffs sold 8,053 shares of the business's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the transaction, the chief executive officer now directly owns 812,193 shares in the company, valued at $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the sale, the insider now owns 207,383 shares in the company, valued at approximately $2,304,025.13. The trade was a 1.08 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,307 shares of company stock valued at $214,703. Insiders own 30.10% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).